|
1
|
Weller M, van den Bent M, Hopkins K, Tonn
JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D,
Henriksson R, Balana C, et al European Association for
Neuro-Oncology (EANO) Task Force on Malignant Glioma: EANO
guideline for the diagnosis and treatment of anaplastic gliomas and
glioblastoma. Lancet Oncol. 15:e395–e403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanai N, Polley MY, McDermott MW, Parsa AT
and Berger MS: An extent of resection threshold for newly diagnosed
glioblastomas. J Neurosurg. 115:3–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diederichs S: The four dimensions of
noncoding RNA conservation. Trends Genet. 30:121–123. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi X, Sun M, Liu H, Yao Y and Song Y:
Long non-coding RNAs: A new frontier in the study of human
diseases. Cancer Lett. 339:159–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang JL, Zheng L, Hu YW and Wang Q:
Characteristics of long non-coding RNA and its relation to
hepatocellular carcinoma. Carcinogenesis. 35:507–514. 2014.
View Article : Google Scholar
|
|
7
|
Fatica A and Bozzoni I: Long non-coding
RNAs: New players in cell differentiation and development. Nat Rev
Genet. 15:7–21. 2014. View
Article : Google Scholar
|
|
8
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhai W, Li X, Wu S, Zhang Y, Pang H and
Chen W: Microarray expression profile of lncRNAs and the
upregulated ASLNC04080 lncRNA in human endometrial carcinoma. Int J
Oncol. 46:2125–2137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ruan W, Wang P, Feng S, Xue Y and Li Y:
Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12)
promotes cell proliferation and migration by upregulating
angiomotin gene expression in human osteosarcoma cells. Tumour
Biol. 37:4065–4073. 2016. View Article : Google Scholar
|
|
11
|
Gong Z, Zhang S, Zeng Z, Wu H, Yang Q,
Xiong F, Shi L, Yang J, Zhang W, Zhou Y, et al: LOC401317, a
p53-regulated long non-coding RNA, inhibits cell proliferation and
induces apoptosis in the nasopharyngeal carcinoma cell line HNE2.
PLoS One. 9:e1106742014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iyer MK, Niknafs YS, Malik R, Singhal U,
Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et
al: The landscape of long noncoding RNAs in the human
transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brennan CM and Steitz JA: HuR and mRNA
stability. Cell Mol Life Sci. 58:266–277. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Filippova N, Yang X, Wang Y, Gillespie GY,
Langford C, King PH, Wheeler C and Nabors LB: The RNA-binding
protein HuR promotes glioma growth and treatment resistance. Mol
Cancer Res. 9:648–659. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heinonen M, Fagerholm R, Aaltonen K,
Kilpivaara O, Aittomäki K, Blomqvist C, Heikkilä P, Haglund C,
Nevanlinna H and Ristimäki A: Prognostic role of HuR in hereditary
breast cancer. Clin Cancer Res. 13:6959–6963. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Denkert C, Koch I, von Keyserlingk N,
Noske A, Niesporek S, Dietel M and Weichert W: Expression of the
ELAV-like protein HuR in human colon cancer: Association with tumor
stage and cyclooxygenase-2. Mod Pathol. 19:1261–1269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Erkinheimo TL, Lassus H, Sivula A,
Sengupta S, Furneaux H, Hla T, Haglund C, Butzow R and Ristimäki A:
Cytoplasmic HuR expression correlates with poor outcome and with
cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer
Res. 63:7591–7594. 2003.PubMed/NCBI
|
|
18
|
Costantino CL, Witkiewicz AK, Kuwano Y,
Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M
and Brody JR: The role of HuR in gemcitabine efficacy in pancreatic
cancer: HuR Up-regulates the expression of the gemcitabine
metabolizing enzyme deoxycytidine kinase. Cancer Res. 69:4567–4572.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
López de Silanes I, Fan J, Yang X,
Zonderman AB, Potapova O, Pizer ES and Gorospe M: Role of the
RNA-binding protein HuR in colon carcinogenesis. Oncogene.
22:7146–7154. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heinonen M, Bono P, Narko K, Chang SH,
Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C and Ristimäki A:
Cytoplasmic HuR expression is a prognostic factor in invasive
ductal breast carcinoma. Cancer Res. 65:2157–2161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho NP, Han HS, Soh Y, Lee KY and Son HJ:
Cytoplasmic HuR over-expression is associated withincreased
cyclooxygenase-2 expression in laryngeal squamous cell carcinomas.
Pathology. 39:545–550. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lim SJ, Kim HJ, Kim JY, Park K and Lee CM:
Expression of HuR is associated with increased cyclooxygenase-2
expression in uterine cervical carcinoma. Int J Gynecol Pathol.
26:229–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ido K, Nakagawa T, Sakuma T, Takeuchi H,
Sato K and Kubota T: Expression of vascular endothelialgrowth
factor-A and mRNA stability factor HuR in human astrocytic tumors.
Neuropathology. 28:604–611. 2008.PubMed/NCBI
|
|
24
|
Ortega AD, Sala S and Espinosa E:
Gonzalez-Baron M and Cuezva JM: HuR and the bioenergetics signature
of breast cancer: a low tumor expression of the RNA-binding protein
predicts a higher risk of disease recurrence. Carcinogenesis.
29:2053–2061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Ellison DW and Figarella-Branger D: World Health Organization
Histological Classification of Tumours of the Central Nervous
System. International Agency for Research on Cancer; France:
2016
|
|
26
|
Louis DN and Ohgaki H; Wiestler O and
Cavenee W: World Health Organization Histological Classification of
Tumours of the Central Nervous System. International Agency for
Research on Cancer; Lyon: 2007
|
|
27
|
Song S, Fajol A, Tu X, Ren B and Shi S:
miR-204 suppresses the development and progression of human
glioblastoma by targeting ATF2. Oncotarget. 7:70058–70065. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arita H, Narita Y, Matsushita Y, Fukushima
S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S and Ichimura
K: Development of a robust and sensitive pyrosequencing assay for
the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol.
32:22–30. 2015. View Article : Google Scholar
|
|
29
|
Arita H, Narita Y, Fukushima S, Tateishi
K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP,
Kawahara N, et al: Upregulating mutations in the TERT promoter
commonly occur in adult malignant gliomas and are strongly
associated with total 1p19q loss. Acta Neuropathol. 126:267–276.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mulholland S, Pearson DM, Hamoudi RA,
Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund
LM, Collins VP, et al: MGMT CpG island is invariably methylated in
adult astrocytic and oligodendroglial tumors with IDH1 or IDH2
mutations. Int J Cancer. 131:1104–1113. 2012. View Article : Google Scholar
|
|
31
|
Wang XP, Shan C, Deng XL, Li LY and Ma W:
Long non-coding RNA PAR5 inhibits the proliferation and progression
of glioma through interaction with EZH2. Oncol Rep. 38:3177–3186.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang P, Chen D, Ma H and Li Y: LncRNA
SNHG12 contributes to multidrug resistance through activating the
MAPK/Slug pathway by sponging miR-181a in non-small cell lung
cancer. Oncotarget. 8:84086–84101. 2017.PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
34
|
Wang L, Ye S, Wang J, Gu Z, Zhang Y, Zhang
C and Ma X: HuR Stabilizes lnc-Sox5 mRNA to Promote Tongue
Carcinogenesis. Biochemistry (Mosc). 82:438–445. 2017. View Article : Google Scholar
|
|
35
|
Zheng J, Liu X, Xue Y, Gong W, Ma J, Xi Z,
Que Z and Liu Y: TTBK2 circular RNA promotes glioma malignancy by
regulating miR-217/HNF1β/Derlin-1 pathway. J Hematol Oncol.
10:522017. View Article : Google Scholar
|
|
36
|
Liang L, Wong CM, Ying Q, Fan DN, Huang S,
Ding J, Yao J, Yan M, Li J, Yao M, et al: MicroRNA-125b
suppressesed human liver cancer cell proliferation and metastasis
by directly targeting oncogene LIN28B2. Hepatology. 52:1731–1740.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He Z, Huang C, Lin G and Ye Y:
siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits
the invasion of human lung cancer SPC-A1 cells. Oncol Rep.
35:1933–1940. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen QN, Wei CC, Wang ZX and Sun M: Long
non-coding RNAs in anti-cancer drug resistance. Oncotarget.
8:1925–1936. 2017.
|
|
39
|
Wang O, Yang F, Liu Y, Lv L, Ma R, Chen C,
Wang J, Tan Q, Cheng Y, Xia E, et al: C-MYC-induced upregulation of
lncRNA SNHG12 regulates cell proliferation, apoptosis and migration
in triple-negative breast cancer. Am J Transl Res. 9:533–545.
2017.PubMed/NCBI
|
|
40
|
Lan T, Ma W, Hong Z, Wu L, Chen X and Yuan
Y: Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12)
promotes tumorigenesis and metastasis by targeting miR-199a/b-5p in
hepatocellular carcinoma. J Exp Clin Cancer Res. 36:112017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Arita H, Yamasaki K, Matsushita Y,
Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M,
Shimizu S, et al: A combination of TERT promoter mutation and MGMT
methylation status predicts clinically relevant subgroups of newly
diagnosed glioblastomas. Acta Neuropathol Commun. 4:792016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Turkalp Z, Karamchandani J and Das S: IDH
mutation in glioma: New insights and promises for the future. JAMA
Neurol. 71:1319–1325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang YA, Ma X, Sathe A, Fujimoto J,
Wistuba I, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, et al:
Validation of SCT methylation as a hallmark biomarker for lung
cancers. J Thorac Oncol. 11:346–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Malmström A, Grønberg BH, Marosi C, Stupp
R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi
ME, et al Nordic Clinical Brain Tumour Study Group (NCBTSG):
Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with
glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol.
13:916–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wick W, Platten M, Meisner C, Felsberg J,
Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M,
et al NOA-08 Study Group of Neuro-oncology Working Group (NOA) of
German Cancer Society: Temozolomide chemotherapy alone versus
radiotherapy alone for malignant astrocytoma in the elderly: The
NOA-08 randomised, phase 3 trial. Lancet Oncol. 13:707–715. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bakheet T, Williams BR and Khabar KS: ARED
3.0: The large and diverse AU-rich transcriptome. Nucleic Acids
Res. 34:D111–D114. 2006. View Article : Google Scholar :
|
|
48
|
Katsanou V, Milatos S, Yiakouvaki A,
Sgantzis N, Kotsoni A, Alexiou M, Harokopos V, Aidinis V, Hemberger
M and Kontoyiannis DL: The RNA-binding protein Elavl1/HuR is
essential for placental branching morphogenesis and embryonic
development. Mol Cell Biol. 29:2762–2776. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Katsanou V, Papadaki O, Milatos S,
Blackshear PJ, Anderson P, Kollias G and Kontoyiannis DL: HuR as a
negative posttranscriptional modulator in inflammation. Mol Cell.
19:777–789. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Streffer JR, Rimner A, Rieger J, Naumann
U, Rodemann HP and Weller M: BCL-2 family proteins modulate
radiosensitivity in human malignant glioma cells. J Neurooncol.
56:43–49. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bolognani F, Gallani AI, Sokol L, Baskin
DS and Meisner-Kober N: mRNA stability alterations mediated by HuR
are necessary to sustain the fast growth of glioma cells. J
Neurooncol. 106:531–542. 2012. View Article : Google Scholar
|
